HC Wainwright Issues Positive Forecast for Humacyte (NASDAQ:HUMA) Stock Price

Humacyte (NASDAQ:HUMA) had its price target upped by HC Wainwright from $6.00 to $12.00 in a research note published on Tuesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Humacyte’s Q3 2024 earnings at ($0.26) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.28) EPS, FY2025 earnings at ($0.76) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.24 EPS and FY2028 earnings at $0.71 EPS.

A number of other research analysts have also recently commented on HUMA. BTIG Research reissued a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. Benchmark restated a “buy” rating and set a $15.00 target price on shares of Humacyte in a report on Thursday, October 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a research report on Friday, September 20th. TD Cowen restated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Finally, EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a report on Monday, September 9th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Humacyte currently has a consensus rating of “Buy” and a consensus price target of $11.00.

Humacyte Trading Up 9.9 %

Shares of Humacyte stock opened at $5.78 on Tuesday. The company’s 50-day moving average price is $5.46 and its 200-day moving average price is $6.13. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61. Humacyte has a 12-month low of $2.08 and a 12-month high of $9.97. The company has a market cap of $689.84 million, a price-to-earnings ratio of -4.59 and a beta of 1.47.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, equities analysts expect that Humacyte will post -1.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Brady W. Dougan sold 252,676 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the sale, the director now owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Brady W. Dougan sold 352,112 shares of the firm’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the completion of the transaction, the director now directly owns 3,677,262 shares in the company, valued at $23,350,613.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brady W. Dougan sold 252,676 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the sale, the director now directly owns 4,306,464 shares in the company, valued at $28,896,373.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,084,153 shares of company stock worth $6,869,996. Company insiders own 11.20% of the company’s stock.

Institutional Investors Weigh In On Humacyte

Several institutional investors and hedge funds have recently made changes to their positions in the company. nVerses Capital LLC bought a new stake in shares of Humacyte in the 2nd quarter worth $28,000. Concurrent Investment Advisors LLC bought a new position in Humacyte during the 3rd quarter valued at about $75,000. Principal Financial Group Inc. purchased a new stake in shares of Humacyte during the 2nd quarter valued at about $83,000. Profund Advisors LLC bought a new stake in shares of Humacyte in the second quarter worth approximately $97,000. Finally, XTX Topco Ltd purchased a new position in shares of Humacyte during the second quarter valued at approximately $110,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.